Lotte Bio launches ADC services; Ypsomed to focus on self-injection business
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lotte Biologics has launched its ADC services and it has signed its ...
View ArticleBristol Myers CEO signals dealmaking will be a top priority in 2025
Is Bristol Myers Squibb ready to take on big dealmaking again? When CEO Chris Boerner took over in late 2023, Bristol Myers was in a difficult position. Its stock price {$BMY} was down more than ...
View ArticleThe potential of all-AI labs
Picture this: A chemist, biologist and computer scientist are working together in a lab. But in this case, they’re all AI agents trained on reams of papers and data, working in a virtual lab run ...
View ArticleHalozyme launches patent fight over Merck's injectable Keytruda
San Diego biotech Halozyme is suing Merck over an injectable version of its blockbuster cancer drug, alleging that the new formulation will infringe on Halozyme's under-the-skin delivery patents. The...
View ArticleCassidy urges major reforms to 340B drug discount program
The growing drug discount program for low-income Americans, known as the 340B program, has "transparency and oversight concerns" and needs to be reformed, Sen. Bill Cassidy (R-LA), chair of the Senate...
View ArticleDrugmakers prepare for manageable tariff hit to business, earnings
For the drug industry, President Donald Trump's tariffs haven't started to really hurt. At least not yet. On Thursday, several of the world’s largest pharma companies — Merck, Bristol Myers Squibb,...
View ArticleBiosimilar launch challenges remain, report finds
As President Donald Trump has sought to speed the development and approval of new biosimilar competition to expensive biologics, only 66% of FDA-approved biosimilars have actually been commercialized,...
View ArticleMerck is well-stocked on Keytruda as pharma tariffs loom, CEO says
Merck CEO Rob Davis told investors on Thursday that he’s confident in the company’s ability to protect its top-selling product from the potential impacts of industry-specific tariffs. Without going...
View ArticleCaribou lays off 32% of staff, cuts lupus program
Caribou Biosciences is paring down its pipeline and cutting about a third of its workforce as cell and gene therapy companies continue to struggle amid a bleak biotech market. Caribou said Thursday...
View ArticleGilead Q1 earnings: Strong HIV business balances out low Covid and cancer...
Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the same amount of revenue compared to this time last year. The Foster City ...
View ArticleMerck KGaA closes in on SpringWorks deal at $3.5B price point
Merck KGaA said Thursday that its late-stage discussions to buy the rare cancer biotech SpringWorks Therapeutics have landed on a likely price of $47 per share. That would put the value of the pending...
View ArticlePaul Stoffels on retiring from Galapagos; Boehringer Ingelheim switches up...
When the board of Belgian biotech Galapagos asked Paul Stoffels to become CEO, he told them he was only interested in doing the job for two to three years. Galapagos — a company he helped found ...
View ArticleAbbVie Q1 earnings: Immunology still a powerhouse as Skyrizi, Rinvoq hit $5B...
One quarter after AbbVie raised future sales estimates due to the successes of its immunology portfolio, the company again saw higher-than-expected revenues to start 2025. AbbVie’s overall revenues for...
View ArticleMerck cuts several Phase 2 programs; Vyne’s Phase 1b psoriasis trial put on...
Plus, news about Verastem Oncology, Oryzon Genomics, Azitra, Vivoryon Therapeutics and Akeso: Merck cuts several Phase 2 programs: The company stopped work on two mid-stage programs testing...
View ArticleAlis Biosciences to press struggling biotechs during downturn
The horde of zombie biotechs lurching ahead and barely surviving has reached a crisis level for some investors. Now there’s a new investment fund targeting these companies. Nicholas Johnston, a...
View ArticleALX Oncology reports Phase 2 failures for CD47 drug combo with Keytruda
ALX Oncology’s efforts to progress a CD47 combo hit a major speed bump. The company said Friday that two trials testing different combinations of its CD47-targeting drug failed to meet their ...
View ArticleAkeso reveals survival data for Keytruda-beating cancer drug
Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes will top Merck's megablockbuster PD-1 drug. As part of the approval, the...
View ArticleRFK Jr. touts program testing ways to pay for sickle cell care
CHARLESTON, SC — HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to improve access to and lower costs for gene therapies for ...
View ArticleCompounding pharmacies dealt blow in semaglutide shortage case
Novo Nordisk scored a major win in its wide-ranging legal fight to keep compounders from making copies of its obesity drug semaglutide. A federal district court in Texas on Thursday denied a request...
View ArticleAmgen invests $900M to expand Ohio biomanufacturing
Amgen is the latest in a series of biopharma companies to announce a massive new US-based investment in manufacturing in response to the Trump administration's call to bring pharma manufacturing to the...
View ArticleAbbVie eyes $10B US expansion amid sector-specific tariff threat
AbbVie CEO Rob Michael said the company will invest $10 billion in the US over the next decade, as the threat of pharmaceutical-specific tariffs looms. AbbVie announced plans in its first-quarter...
View ArticleFDA chief Makary talks expediting drug approvals, RIFs and the abortion pill
FDA Commissioner Marty Makary is ramping up his public presence, recently sitting for an interview with Megyn Kelly and participating in an HHS event on removing some dyes from the American food...
View ArticleEarnings season is upon us; Makary on rare disease; Startup is first to...
Welcome back to Endpoints Weekly! Our team of reporters covered first-quarter earnings results from a handful of companies this week. See below for pharma executives’ comments on tariff exposure,...
View ArticleJ&J reports durability data for bladder cancer 'pretzel' drug
Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a year, according to the latest data cut from a registrational trial....
View Article